Cargando…

Platelet-derived serotonin links vascular disease and tissue fibrosis

Vascular damage and platelet activation are associated with tissue remodeling in diseases such as systemic sclerosis, but the molecular mechanisms underlying this association have not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) stored in platelets strongly ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Dees, Clara, Akhmetshina, Alfiya, Zerr, Pawel, Reich, Nicole, Palumbo, Katrin, Horn, Angelika, Jüngel, Astrid, Beyer, Christian, Krönke, Gerhard, Zwerina, Jochen, Reiter, Rudolf, Alenina, Natalia, Maroteaux, Luc, Gay, Steffen, Schett, Georg, Distler, Oliver, Distler, Jörg H.W.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092343/
https://www.ncbi.nlm.nih.gov/pubmed/21518801
http://dx.doi.org/10.1084/jem.20101629
Descripción
Sumario:Vascular damage and platelet activation are associated with tissue remodeling in diseases such as systemic sclerosis, but the molecular mechanisms underlying this association have not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) stored in platelets strongly induces extracellular matrix synthesis in interstitial fibroblasts via activation of 5-HT(2B) receptors (5-HT(2B)) in a transforming growth factor β (TGF-β)–dependent manner. Dermal fibrosis was reduced in 5-HT(2B)(−/−) mice using both inducible and genetic models of fibrosis. Pharmacologic inactivation of 5-HT(2B) also effectively prevented the onset of experimental fibrosis and ameliorated established fibrosis. Moreover, inhibition of platelet activation prevented fibrosis in different models of skin fibrosis. Consistently, mice deficient for TPH1, the rate-limiting enzyme for 5-HT production outside the central nervous system, showed reduced experimental skin fibrosis. These findings suggest that 5-HT/5-HT(2B) signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT(2B) as a novel therapeutic target to treat fibrotic diseases.